Lakefront Biotherapeutics (LKFT) Equity Income (2023 - 2024)
Lakefront Biotherapeutics (LKFT) posted quarterly Equity Income of $102.7 million for Q1 2024, up 288.76% year-on-year from $26.4 million in Q2 2023, and up 288.76% on a QoQ basis from $26.4 million in Q1 2023.
Lakefront Biotherapeutics (LKFT) Equity Income (2023 - 2024) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Equity Income for 2 consecutive years, with $102.7 million the latest figure, recorded in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 102.67 Mn |
| Mar 31, 2023 | 26.41 Mn |